Skip to main content


You are here

MD+DI: Straight Out of Stealth Mode: Protaryx Raises $8M

Wednesday, July 1, 2020

The Baltimore, MD-based company will use the proceeds to help develop its device for precision transseptal access to the left atrium during structural heart and catheter ablation procedures.
The time is just right for Protaryx Medical. The Baltimore, MD-based company announced it has raised $8 million in a series A round and is coming out of stealth mode.

Protaryx said its device is intended for an early and important procedure, transseptal access, which allows a physician to move from the right atrium to the left atrium of the heart. The firm said it’s important for patients who may be in need of mitral valve repair or replacement; left atrial appendage closure or an ablation procedure in the left atrium.

“We really think our technology is first-in-class,” Terri Burke, CEO and co-founder of Protaryx, told MD+DI.  “It delivers 3-dimensional control for a reliable crossing. It’s the only device where you can move in three different directions independently from each other.”

Burke said the concept behind the device Protaryx’s co-founder Dr. James Gammie, who is the chief of cardiac thoracic surgery at the University of Maryland.

Read the full story from MD+DI.